Sorafenib and Regorafenib in HBV- Or HCV-positive Hepatocellular Carcinoma Patients: Analysis of RESORCE and SHARP Trials

Digestive and Liver Disease - Netherlands
doi 10.1016/j.dld.2017.04.022
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Seroprevalence of HBV and HCV in Primary Hepatocellular Carcinoma Patients in Zimbabwe

Infectious Agents and Cancer
Cancer ResearchEpidemiologyOncologyInfectious Diseases
2009English

Successful Treatment of Hepatocellular Carcinoma With Regorafenib After Sorafenib-Induced Hypersensitivity

Internal Medicine
Internal MedicineMedicine
2019English

Efficacy of Regorafenib in Hepatocellular Carcinoma Patients: A Systematic Review and Meta-Analysis

Cancers
Cancer ResearchOncology
2019English

Sorafenib in Hepatocellular Carcinoma

Clinical Medicine. Therapeutics
2009English

Prevalence of Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) in Hepatocellular Carcinoma Patients Attending a Cancer Hospital

IOSR Journal of Dental and Medical Sciences
2017English

Sorafenib vs Nivolumab in Patients With Hepatocellular Carcinoma

Journal of Liver Research, Disorders & Therapy
2017English

Retrospective Analysis of Transarterial Chemoembolization and Sorafenib in Chinese Patients With Unresectable and Recurrent Hepatocellular Carcinoma

Oncotarget
Oncology
2016English

Sorafenib Continuation or Discontinuation in Patients With Unresectable Hepatocellular Carcinoma After a Complete Response

Oncotarget
Oncology
2015English

Differential Metabonomic Profiles of Primary Hepatocellular Carcinoma Tumors From Alcoholic Liver Disease, HBV-infected, and HCV-infected Cirrhotic Patients

Oncotarget
Oncology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy